Lipid-lowering treatment in coronary artery disease: How low should cholesterol go?

Drugs

Volumn 59, Issue 5, 2000, Pages 1127-1135

  Jones, Peter H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; COLESTYRAMINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN;

ANGIOPLASTY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; HIGH RISK POPULATION; HUMAN; REVIEW; RISK ASSESSMENT;

EID: 0034036362     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059050-00008     Document Type: Review

References (30)

1. 1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344 (8934): 1383-9
2. 2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
3. 3. Shepherd J, Cobbe SM, Ford I, el al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
4. 4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPSA/TexCAPS. JAMA 1998; 279: 1615-22
5. 5. The Long-Term Intervention with Pravastatin in Ishemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
6. 6. Roussouw JE. Lipid-lowering interventions in angiographic trials. Am J Cardiol 1995; 76: 86C-92
7. 7. National Cholesterol Education Program. Second report of the expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994; 89: 1329-445
8. 8. Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 1998; 97: 1446-52
9. 9. Jacobs DR, Blackburn H, Higgins M. Report of the conference on low blood cholesterol: mortality associations. Circulation 1992; 86: 1046-60
10. 10. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-8
11. 11. Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in populations with low cholesterol concentrations. BMJ 1991; 303: 276-82
12. 12. Klag MJ, Ford DE, Mead LA, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 1993; 328: 313-8
13. 13. Muldoon MF, Manuch SB, Mathews KA. Lowering cholesterol concentrations and mortality quantitative review of primary prevention trials. BMJ 1990; 301: 309-14
14. 14. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ 1994; 308: 373-9
15. 15. Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ 1993; 306: 1367-73
16. 16. Committee of Principal Investigators. WHO Cooperative Trial on primary prevention of ischemic heart disease using elofibrate to lower serum cholesterol: mortality follow up. Lancet 1980; II: 379-85
17. 17. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64
18. 18. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-81
19. 19. Frick MH, Elo MO, Haapa K, et al. Helsinki heart sludy: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safely of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45
20. 20. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998; 97: 1436-9
21. 21. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-5
22. 22. Pederson TR, Olsson AC, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Study (45). Circulation 1998; 97: 1453-60
23. 23. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation of obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336: 153-62
24. 24. Campeau L, Hunninghake DB, Kratterud GL, et al. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors: NHLBI Post Coronary Artery Bypass Graft Clinical Trial. Circulation 1999; 99: 3241-7
25. 25. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70-6
26. 26. Jones PH, Kafonek S, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, Invastalin and fluvastatin in patients with hypercholesterolemia. Am J Cardiol 1998; 81: 582-7
27. 27. Stein EA, Davidson MH, Dobs HS, et al. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolaemic patients. Am J Cardiol 1998; 82: 311-6
28. 28. Stein E. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. Am J Cardiol 1998; 82: 40J-6
29. 29. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1999; Suppl. I: 56S-9
30. 30. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-8